376 related articles for article (PubMed ID: 27556189)
1. Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma.
Li Y; Liu J; Huang B; Chen M; Diao X; Li J
Oncotarget; 2017 Apr; 8(15):25637-25649. PubMed ID: 27556189
[TBL] [Abstract][Full Text] [Related]
2. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
3. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
[TBL] [Abstract][Full Text] [Related]
4. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
5. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of [
Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
[TBL] [Abstract][Full Text] [Related]
7. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.
Nanni C; Zamagni E; Farsad M; Castellucci P; Tosi P; Cangini D; Salizzoni E; Canini R; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):525-31. PubMed ID: 16453155
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
9. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma.
Haznedar R; Akı SZ; Akdemir OU; Ozkurt ZN; Ceneli O; Yağcı M; Sucak GT; Unlü M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1046-53. PubMed ID: 21287167
[TBL] [Abstract][Full Text] [Related]
10. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of
Tu H; He Y; Huang T; Choe S; Lan X; Duan X; Sattar H; Li C; Zhou F
Eur J Haematol; 2018 Feb; 100(2):189-197. PubMed ID: 29226428
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using
Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H
Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Baseline
Moon SH; Choi WH; Yoo IR; Lee SJ; Paeng JC; Jeong SY; Lee SW; Kim K; Choi JY
Korean J Radiol; 2018; 19(3):481-488. PubMed ID: 29713226
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
[TBL] [Abstract][Full Text] [Related]
15. PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.
Zamagni E; Nanni C; Mancuso K; Tacchetti P; Pezzi A; Pantani L; Zannetti B; Rambaldi I; Brioli A; Rocchi S; Terragna C; Martello M; Marzocchi G; Borsi E; Rizzello I; Fanti S; Cavo M
Clin Cancer Res; 2015 Oct; 21(19):4384-90. PubMed ID: 26078390
[TBL] [Abstract][Full Text] [Related]
16. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).
Nanni C; Zamagni E; Versari A; Chauvie S; Bianchi A; Rensi M; Bellò M; Rambaldi I; Gallamini A; Patriarca F; Gay F; Gamberi B; Cavo M; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):414-21. PubMed ID: 26475305
[TBL] [Abstract][Full Text] [Related]
17. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
18. Prospective Evaluation of Magnetic Resonance Imaging and [
Moreau P; Attal M; Caillot D; Macro M; Karlin L; Garderet L; Facon T; Benboubker L; Escoffre-Barbe M; Stoppa AM; Laribi K; Hulin C; Perrot A; Marit G; Eveillard JR; Caillon F; Bodet-Milin C; Pegourie B; Dorvaux V; Chaleteix C; Anderson K; Richardson P; Munshi NC; Avet-Loiseau H; Gaultier A; Nguyen JM; Dupas B; Frampas E; Kraeber-Bodere F
J Clin Oncol; 2017 Sep; 35(25):2911-2918. PubMed ID: 28686535
[TBL] [Abstract][Full Text] [Related]
19. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
[TBL] [Abstract][Full Text] [Related]
20. Role of
Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
